Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1017P - AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)

Date

10 Sep 2022

Session

Poster session 14

Topics

Clinical Research

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Yan Yu

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

Y. Yu1, D. Huang2, B. Gao3, J. Zhao4, Y. Hu5, W. Zhuang6, S. Kao7, W. Xu8, Y. Yao9, T. Yang10, Y. Lee11, J. Kim12, H. Shiah13, R. Wang14, H. Zheng15, W. Tan16, R. Gao14, H.R. Kim17, S. Lu18

Author affiliations

  • 1 Department Of Internal Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, na - Harbin/CN
  • 2 Department Of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin/CN
  • 3 Blacktown Cancer And Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, 2148 - Blacktown/AU
  • 4 Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education/beijing), Department Of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, 100142 - Beijing/CN
  • 5 Department Of Thoracic Oncology, Hubei Cancer Hospital, 430079 - Wuhan/CN
  • 6 Department Of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, 350014 - Fuzhou/CN
  • 7 Department Of Medical Oncology, Chris O’Brien Lifehouse, 2050 - Camperdown/AU
  • 8 Division Of Cancer Services, Princess Alexandra Hospital, Brisbane/AU
  • 9 Department Of Oncology, First Hospital, Medical College, Xi'an Jiaotong University, Xi'an/CN
  • 10 Division Of Chest Medicine, Department Of Internal Medicine, Taichung Veterans General Hospital, Taichung/TW
  • 11 Department Of Medical Oncology, National Cancer Center, Goyang/KR
  • 12 Department Of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul/KR
  • 13 Division Of Hematology And Oncology, Department Of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei/TW
  • 14 Clinical Development, BeiGene (Shanghai) Co., Ltd., Shanghai/CN
  • 15 Biostatistics, BeiGene USA, Inc., San Mateo/US
  • 16 Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., Beijing/CN
  • 17 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul/KR
  • 18 Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1017P

Background

T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) inhibitor + an anti-programmed cell death protein 1 (PD-1) antibody is a promising combination which shows potent efficacy in solid tumors. AdvanTIG-105 is a Phase 1/1b open-label study designed to assess the safety and preliminary antitumor activity of OCI, an anti-TIGIT monoclonal antibody (mAb), + TIS, an anti-PD-1 mAb, in pts with metastatic unresectable solid tumors (NCT04047862). In the dose-escalation part, OCI + TIS was well tolerated, preliminary efficacy was observed, and the recommended Phase 2 dose (RP2D) of OCI 900 mg intravenous (IV) every three weeks (Q3W) + TIS 200 mg IV Q3W was established. We report results from the dose-expansion (Cohorts 1 [C1] & 2 [C2]) of the AdvanTIG-105 study.

Methods

Treatment-naïve adult pts with histologically/cytologically confirmed metastatic sq (C1) or non-sq with EGFR/ALK/ROS-1 wild-type tumors (C2) NSCLC were enrolled. Pts in C1 received the RP2D of OCI + TIS with paclitaxel/nab-paclitaxel + carboplatin and pts in C2 received the RP2D of OCI + TIS with pemetrexed + cisplatin/carboplatin, both until disease progression, intolerable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST v1.1. Secondary endpoints included safety.

Results

As of March 18, 2022, 84 pts were enrolled (C1: n=41; C2: n=43). The median study follow-up was 17.7 weeks (range 1.1–42.6) in C1 and 15.0 weeks (3.0–51.1) in C2. Of the 76 efficacy-evaluable pts, the confirmed ORR in C1 was 45.9% (95% confidence interval [CI]: 0.3, 0.6) and 25.6% (95% CI: 0.1, 0.4) in C2. In total, 81 pts (96.4%) experienced ≥ 1 treatment-emergent adverse event (TEAE), and 48 pts (57.1%) had ≥ Grade 3 TEAEs. Serious TEAEs occurred in 26 pts (31.0%). The most common TEAEs were anemia (41.7%), neutrophil count decreased (33.3%), and white blood cell count decreased (33.3%).

Conclusions

The RP2D of OCI 900 mg IV Q3W and TIS 200 mg IV Q3W + chemo was generally well tolerated and showed antitumor activity in pts with treatment-naïve metastatic sq/non-sq NSCLC. Prof. Y. Yu and Prof. D. Huang have contributed equally to the study.

Clinical trial identification

NCT04047862.

Editorial acknowledgement

Medical writing support, under the direction of the authors, was provided by Victoria Dagwell, MSc, and Helena Crisford, MSc, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene, Ltd.

Legal entity responsible for the study

BeiGene, Ltd.

Funding

BeiGene, Ltd.

Disclosure

S. Kao: Financial Interests, Invited Speaker: Roche, MSD, BMS, Pfizer, AZ, Specialised Therapeutic; Financial Interests, Advisory Board: Takeda, Pfizer, Roche, Boehringer, Lilly, MSD, Specialised Therapeutics; Financial Interests, Research Grant: AZ. W. Xu: Financial Interests, Invited Speaker: Merck, MSD, AZD; Financial Interests, Advisory Board: MSD, Merck, Novartis; Financial Interests, Research Grant: Merck. J. Kim: Financial Interests, Expert Testimony: CJ Healthcare; Financial Interests, Member of the Board of Directors: IMBdx; Financial Interests, Research Grant: AstraZeneca, Boehringer Ingelheim, Sanofi, Lilly, CJ Healthcare, Ono Pharmaceutical, Pfizer, Novotech, Astellas Pharma, Merck, Alpha Biopharma, Yuhan, MSD, IL-Yang Pharm; Financial Interests, Advisory Role: CJ HealthcareAbion Inc. R. Wang: Financial Interests, Full or part-time Employment: BeiGene, Ltd. H. Zheng: Financial Interests, Full or part-time Employment: BeiGene USA; Financial Interests, Stocks/Shares: BeiGene USA. W. Tan: Financial Interests, Full or part-time Employment: BeiGene, Ltd.; Financial Interests, Stocks/Shares: BeiGene, Ltd. R. Gao: Financial Interests, Full or part-time Employment: BeiGene, Ltd. S. Lu: Financial Interests, Invited Speaker: AstraZeneca, Roche, Hansoh; Financial Interests, Advisory Board: AstraZeneca, Pfizer, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co. Ltd., Mirati Therapeutics Inc, Roche; Financial Interests, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui BeiGene and Roche, Hansoh; Financial Interests, Principal Investigator: AstraZeneca, Hutchison, Heng Rui BeiGene and Roche, Hansoh. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.